Convalescent plasma for people with COVID-19: a living systematic review

Keyphrases

• COVID-19 100%
• Convalescent Plasma 100%
• Living Systematic Review 100%
• Randomized Controlled Trial 88%
• Confidence Interval 72%
• Risk Ratio 56%
• All-cause Mortality 24%
• Placebo 20%
• Mild Disease 20%
• Event Risk 20%
• Moderate to Severe 16%
• Severe Disease 16%
• Serious Adverse Events 16%
• Adverse Events 12%
• Symptom Resolution 12%
• Odds Ratio 8%
• Risk of Death 8%
• New Evidence 8%
• Antibody Detection 8%
• Admission to Hospital 8%
• Human Immunoglobulin 8%
• Cochrane 8%
• Trial Reporting 8%
• Coronavirus Disease (COVID) 8%
• Confirmed Diagnosis 8%
• Convalescent Plasma Therapy 8%
• Admission-to-death 8%
• Invasive Mechanical Ventilation 8%
• Europe 4%
• South-East Asia 4%
• Infectious Diseases 4%
• Severe Acute Respiratory Syndrome 4%
• Hospital Admission 4%
• Africa 4%
• World Health Organization 4%
• Selection Criteria 4%
• Symptom Onset 4%
• Global Literature 4%
• Clinical Status 4%
• Comorbidity 4%
• MEDLINE 4%
• Embase 4%
• Review Update 4%
• Immunoglobulin 4%
• Quality of Life 4%
• Disease Severity 4%
• Hazard Ratio 4%
• Viral Respiratory Infections 4%
• In-hospital Death 4%
• Multiple Regions 4%
• Western Pacific 4%
• Eastern Mediterranean Region 4%
• Clinical Improvement 4%
• Middle East Respiratory Syndrome 4%
• Quality of Life Impact 4%
• Potential Therapy 4%
• Single-center Study 4%
• Search Methods 4%
• Clinical Worsening 4%
• GRADE Approach 4%
• Asymptomatic Diseases 4%
• Certainty of Evidence 4%
• Initial Symptom 4%
• Disease Research 4%
• Trial Registries 4%
• Epistemonikos 4%
• Severe Acute Respiratory syndrome-CoV-2 4%
• RoB 2 4%
• Country Income Groups 4%

Pharmacology, Toxicology and Pharmaceutical Science

• Randomized Controlled Trial 100%
• Coronavirinae 100%
• Diseases 100%
• Adverse Event 31%
• All Cause Mortality 27%
• Placebo 22%
• Human Immunoglobulin 9%
• Severe Acute Respiratory Syndrome 9%
• Infection 4%
• Immunoglobulin 4%
• Disease Severity 4%
• Viral Respiratory Tract Infection 4%
• Middle East Respiratory Syndrome 4%
• Comorbidity 4%

Neuroscience

• Coronavirinae 100%
• Coronavirus 100%
• Blood Plasma 100%
• Randomized Controlled Trial 70%
• Placebo 16%
• Human Immunoglobulin 6%
• Mechanical Ventilation 6%
• Intravenous Immunoglobulin 3%
• Middle East Respiratory Syndrome 3%
• Viral Respiratory Tract Infection 3%
• Comorbidity 3%